Advantages

・It provides amino sequences adaptable to human antibody.
・No experimental findings with animals are required.
・The target site of an antigen can be selected as you like.
・It takes only about 1 month to obtain monoclonal antibodies.
・Low costs, compared with the conventional method.

Current Stage and Key Data

This technology has already produced several designed monoclonal antibodies. The binding affinities are confirmed by isothermal titration calorimetry.

Partnering Model

・Paid contract research conducted on behalf of pharmaceutical companies to obtain a monoclonal antibody.
・Handling the results of the contract research is negotiable.

Background

In the conventional method of acquiring antibodies by immunizing animals such as mice, it is difficult to produce antibodies that bind to the desired target site of the antigen. Our technique is possible to produce human antibodies aiming at the desired site if structural information of the site is available.
The basis of our technology has been published (references below). We are conducting joint research with many academics in Japan and overseas for practical application.

Principal Investigator

Tyuji Hoshino
(Laboratory of Molecular Design, Graduate School of Pharmaceutical Science, Chiba University)

Patents and Publications

J. Chem. Inf. Model. 61, 2396-2406 (2021)
J. Phys. Chem. B 125, 11374-11385 (2021)